EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases

The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).

Sex

All

Minimum age

18 Years

Maximum age

70 Years

Inclusion Criteria:

1. Patients with solid masses (diameter \> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.
2. Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT/MRI).
3. Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.
4. Signed informed consent form.
5. Patients must be able to comply with the trial requirements.

Exclusion Criteria:

1. Patients with other active malignant tumors
2. Patients with coagulation dysfunction (PLT 50,000/mm3, INR \> 1.5; roughly estimated, INR \> 1.5 is approximately equivalent to PT \> 18 seconds)
3. Pregnant women
4. Patients with hemorrhagic diseases
5. Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week
6. Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics
7. Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc.
8. Patients with known hepatitis C virus infection
9. Patients with known human immunodeficiency virus (HIV) infection
10. Patients with imaging examinations, EUS results, etc., suggesting pancreatic cystic space-occupying lesions
11. Patients who have received radiotherapy or chemotherapy
12. Patients with incomplete pathological information, unable to make a clear diagnosis, or unable to sign the informed consent form

• RESULTChen L, Chen M, Chen J. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Mar 25;20(3):357-360. Chinese. PMID 28338171
• RESULTCatenacci DV, Chapman CG, Xu P, Koons A, Konda VJ, Siddiqui UD, Waxman I. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology. 2015 Dec;149(7):1794-1803.e4. doi: 10.1053/j.gastro.2015.08.050. Epub 2015 Sep 2. PMID 26341722
• RESULTWang JX, Lu LG, Cai XB. Endoscopic ultrasound for the diagnosis and treatment of primary hepatocellular carcinoma. J Dig Dis. 2024 Mar;25(3):156-162. doi: 10.1111/1751-2980.13266. Epub 2024 Apr 17. PMID 38628105
• RESULTZhu Z, Zhang Y, Zhang W, Tang D, Zhang S, Wang L, Zou X, Ni Z, Zhang S, Lv Y, Xiang N. High-throughput enrichment of portal venous circulating tumor cells for highly sensitive diagnosis of CA19-9-negative pancreatic cancer patients using inertial microfluidics. Biosens Bioelectron. 2024 Sep 1;259:116411. doi: 10.1016/j.bios.2024.116411. Epub 2024 May 20. PMID 38781696
• RESULTChinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. [Guidelines for the diagnosis and treatment of pancreatic cancer in China(2021)]. Zhonghua Wai Ke Za Zhi. 2021 Jul 1;59(7):561-577. doi: 10.3760/cma.j.cn112139-20210416-00171. Chinese. PMID 34256456
• RESULTPark W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021 Sep 7;326(9):851-862. doi: 10.1001/jama.2021.13027. PMID 34547082
• RESULTIelpo B, Caruso R, Duran H, Diaz E, Fabra I, Malave L, Ferri V, Alvarez R, Cubillo A, Plaza C, Lazzaro S, Kalivaci D, Quijano Y, Vicente E. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surg Oncol. 2017 Dec;26(4):402-410. doi: 10.1016/j.suronc.2017.08.003. Epub 2017 Aug 24.